Parliament strengthens public health slant on EU pharma proposals
This article was originally published in SRA
The European Parliament’s rapporteurs for the draft European Union legislation on pharmacovigilance and counterfeit medicines have amended the proposals to put more emphasis on the need to ensure the protection of public health.
You may also be interested in...
The UK life sciences trade group says the “ill-considered” guidance will result in duplicative and costly repetition and dent industry’s confidence in the government’s competence.
The Australian government is investing in two candidate vaccines being developed in Melbourne, French firm Avaxia is looking at the virucidal potential of an antibacterial compound, and Canada has ordered millions of specialist vials and syringes from an advanced materials science firm based in Alabama.
As the final scheduled round of post-Brexit trade talks begins amid growing concern over the prospect of a deal and the pervasive threat of COVID-19, the pharmaceutical industry in the UK and the EU have issued an urgent call for an MRA on medicines GMP. They also want to see a one-year phase-in of medicines-related aspects of the Northern Ireland Protocol.